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Summary: Previously symptomatic and permanently asymptomatic carriers of a gene mutation for acute intermit-
tent porphyria as well as matched controls were screened with regard to a series of variables of possible relevance
to the development of porphyric symptoms. The basis for the study was a concept of acute porphyria as a condition
of a permanent system overload of oxidative stress, with long term effects on hepatic and renal tissue, and with
instances of periodic overload of free radicals giving rise to acute neurologic involvement.
Leukocyte concentrations of manganese, calcium, iron and zinc, as well as erythrocyte calcium differed between
the groups, acute intermittent porphyria gene carriers, irrespective of previous porphyric illness, showing signifi-
cantly higher levels than the controls.
Manganese was found to be the most discriminative component of all the 78 variables investigated, accounting for
about 98 per cent of the variance between the groups. An increment, by a factor of four, in cellular manganese is
suggestive of an increase, in acute intermittent porphyria, of a manganese associated enzyme, e. g. glutamine
synthetase, pyruvate carboxylase or mitochondrial Superoxide dismutase. The best fit into the model considered is
provided by a theory focused on Superoxide dismutase, induced in response to Superoxide anion radical produced
from aminolaevulinic acid. In porphyria gene carriers seemingly resistent to porphyric manifestations, an increase
in potentially prooxidant cellular iron is matched by a proportional increment in manganese, i.e. presumably by a
corresponding mitochondrial Superoxide dismutase induction. This mechanism is not operative in porphyric individ-
uals prone to development of neuropsychiatric symptoms.
In acute intermittent poiphyria with a history of porphyric illness there is a positive correlation between erythrocyte
manganese and serum folate and a negative correlation between leukocyte ferrochelatase activity and serum cobal-
amin concentration. This may mirror a role of the cobalamin-folate system in the acute porphyric process.
1) This work was supported by grants from the Karolinska Insti- Glyoxalase I (EC 4.4.1.5)
tute. Porphobilinogen deaminase (EC 4.3,1.8)
2) Enzymes listed in the text: Porphobilinogen synthase (aminolaevulinate dehydratase)
Catalase (EC 1.11.1.6) (EC 4.2.1.24)
Coproporphyrinpgen oxidase (EC 1.3.3.3) Protoporphyrinogen oxidase (EC 1.3.3.4)
Ferrochelatase (EC 4.99.1.1) Superoxide dismutase (EC 1.15.1.1)
Glutamine synthetase (EC 6.3.1.2) Uroporphyrinogen decarboxylase (EC 4.1.1.37)
Glutathione peroxidase (EC 1.11.1.9)
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In the acute intermittent porphyria gene carrier state, activities of erythrocyte uroporphyrinogen decarboxylase as
well as porphobilinogen deaminase are decreased. The decrease is associated with the active state of the disorder.
A correlation between the activities of the two erythrocyte enzymes in non-porphyric individuals is absent in acute
intermittent poiphyria.
In acute intermittent porphyria with a history of porphyric illness, red cell porphobilinogen synthase (aminolaevuli-
nate dehydratase) activity is higher than in the permanently asymptomatic cases and the controls. The increased
enzyme activity is connected with recent activation of the porphyric condition.
Gene carriers of acute intermittent porphyria with a history of porphyric symptoms have a significantly higher
intake of sucrose containing foodstuff. In other respects the three groups do not differ in food consumption patterns,
nor in smoking or alcohol ingestion.
Introduction
The acute hepatic porphyrias comprise a group of hered-
itary disorders of haem metabolism. Attacks of general-
ized neuropathy occur in some of the porphyria gene
carriers, not seldom with disablement as a result, and
occasionally with fatal outcome. Since no cure for the
genetic condition is yet available, the therapeutic strat-
egy is concentrated on prophylactic measures aimed at
avoiding porphyrinogenic environmental factors of no-
torious significance. Early recognition of the gene car-
rier condition is of greatest importance.
A number of hypotheses have been advanced regarding
the pathogenesis of the neuropsychiatric symptoms. Fo-
cal ischaemic or necrotic cerebral lesions found at au-
topsy, and magnetic resonance findings of transient
multifocal brain lesions similar to those seen in verified
vasculopathies, have provided support for a vascular
theory (1). No perceivable neuropathologic findings or
observations of mild patchy neuronal losses and demye-
lination have favoured hypotheses focused on metabolic
aberrations. These could be operating through overpro-
duction of neuroactive compounds or substances with
direct or indirect toxic effects on nerve tissue, e.g. 5-
aminolaevulinic acid, or through deficits in haem based
factors necessary for the energy supply of the nervous
system, e. g. the cytochromes of terminal oxidation (2).
However, no definite explanation for the background of
the neurologic disturbances in acute porphyria has yet
emerged. Even less well understood is why some carri-
ers of a porphyria gene mutation do not develop clinical
manifestations in spite of even extreme exposure to por-
phyria precipitating agents (3, 4), while others are se-
verely affected even when closely following prophylac-
tic advice. It would be of considerable medical interest
to be able to identify the porphyric individuals who are
at risk for symptom development. In the present study a
biochemical screening was undertaken with the hope to
elucidate pathogenetic mechanisms behind the clinical
manifestations in acute porphyria, and thus to find mark-
ers for porphyric vulnerability. The choice of screening
variables was based on the concept that overproduction
of 5-aminolaevulinic acid is the key event in the meta-
bolic process leading to neurological manifestations in
porphyria. The reason was that all metabolic distur-
bances characterized by accumulation of 5-aminolaevul-
inic acid are accompanied by neurologic symptoms, i. e.,
tyrosinaemia, lead intoxication and the four types of
acute hepatic porphyria. Also, during a porphyric attack
the severity of the clinical condition is closely mirrored
by the magnitude of the 5-aminolaevulinic acid accumu-
lation, as monitored by urinary analysis (5). According
to the model applied (fig. 1) the overproduction of 5-
aminolaevulinic acid is the result of a combination of an
increased rate of formation, secondary to the induction
of the enzyme generating the compound, and a decrease
in its rate of further transformation, dependent on genet-
ically determined catalytic blocks downstream of the
haem synthetic pathway. The inductive process is trig-
gered by reductions in the size of the free intracellular
haem pool, the situation at hand when the production of
the compound is unsufficient for the prevailing synthetic
demands (5). It is known that most transition elements
and heavy metals regulate haem biosynthetic and degrä-
dative activities (6-9). It may therefore be suspected
that these elements are able to influence the mechanisms
triggering the porphyric symptoms, and thus the pheno-
typic expression in porphyria. Differences in the activi-
ties of enzymes2) involved in haem synthesis, possibly
caused by trace elements, may be another explanation
for interindividual differences in porphyric morbidity.
Aminolaevulinic acid does not seem to be directly
neurotoxic (10), but may under certain conditions give
rise to extremely toxic molecular species. Thus it has
been shown that 5-aminolaevulinic acid is a potent gen-
erator of oxygen radicals and it has been proposed that
it might generate in situ active oxygen species responsi-
ble for nerve binding site destruction (11, 12). Conse-
quently, the free radical character of S^aminolaevulinic
acid has been implicated in the pathophysiology of acute
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porphyria (13). If the neurological involvement in por-
phyria should be dependent on free radical attacks on
the nervous tissues, differences in the interplay between
radical enhancing and protecting factors would explain
the varying vulnerability evident in these disorders. Key
components in this process would be the antioxidant en-
zymes Superoxide dismutase2) and glutathione peroxi-
dase2) which, respectively, converts the initially gener-
ated Superoxide anion radical to hydrogen peroxide, and
prevents the formation of highly toxic hydroxyl radical
from this compound. At higher concentrations of hy-
drogen peroxide, the activity of the haem-based enzyme
catalase2) becomes more and more important for the cir-
cumventation of the hydroxyl radical generating step of
the four electron pathway for oxygen reduction (14).
Thus, gene carriers with and without a history of porph-
yric symptoms were compared with regard to a series of
variables with possible bearing to the proposed patho-
genesis of the manifestations. The main areas explored
were trace element profiles, haem synthetizing enzyme
catalytic activities and components signalling oxidative
stress. Differences in demands for cytochrome P-450 de-
toxification of compounds ingested via food, alcoholic
beverages or by smoking may be of significance as well,
since induction of this enzyme system may drain the
hepatocyte free intracellular haem pool and thus en-
hance the traffic through the haem synthetic pathway to
the point of overload. Food consumption patterns and
smoking and alcohol consumption habits were therefore
included in the study. In order to unmask subclinical
illness able to invalidate the matching between the
groups, a series of serum and blood markers for disease
were investigated as well. A total of 78 variables were
compared between the two matching groups of por-
phyria gene carriers, and between these two groups indi-
vidually and a matched control group of non-carriers.
Materials and Methods
Protocol
Carriers of a gene for acute intermittent porphyria with and without
a history of porphyric symptoms, as well as matched controls, were
compared with regard to a series of blood, food, alcohol consump-
tion and smoking variables. The quantities investigated are pre-
sented in table 1.
Acute intermittent porphyria gene carriers and control
persons
Twenty presently asymptomatic gene carriers of acute intermittent
porphyria, 10 with and 10 without a history of porphyric symp-
toms, were randomly selected from 50 previously diagnosed acute
intermittent porphyria patients living in the municipality of Ar-
jeplog in northern Sweden. Diagnosis of acute intermittent por-
phyria was assessed by the fact that the individual belonged to a
kindred with recognized acute intermittent porphyria, and by the
finding of an exon 10, 198 Τφ —» stop mutation in the porphobili-
nogen deaminase2) gene (15), demonstrated to be specific for the
acute intermittent porphyria condition (16). Within the group of
previously symptomatic acute intermittent porphyria the individ-
uals were classified with regard to the number of porphyric attacks
experienced, to recentness of the last attack and to the severity of
the symptoms. All the 10 individuals had a history of attacks of
abdominal pain and increased urinary porphobilinogen excretion.
Six in addition had been victims of psychiatric disturbances and 3
of neurological symptoms. None had any clinical manifestations at
the time of the study. Three individuals had experienced porphyric
symptoms during the month before the start of the study, three
during the year preceeding the last month, and four during the four
years preceeding the last year. Four of the six patients with previ-
ous acute intermittent porphyria symptoms had, during the last
year, suffered from attacks one to three times. The remaining two
had experienced more than four attacks. Severity of the clinical
manifestion was assessed by the physician responsible for the treat-
ment and classification of the patients. On the basis of symptom-
atology and magnitude of the therapeutic efforts, three individuals
were estimated to have been more severely affected than the rest.
In the acute intermittent porphyria gene carrier group one 74 year
old woman had rheumatoid arthritis and an erythrocyte sedimenta-
tion rate of 52 mm (reference range 2—20 mm). Six had hyperten-
sive disease, two diabetes mellitus, one haemochromatosis and one
had periods of alcohol abuse. By their own expressed opinion, and
based on physical examination and laboratory tests the rest of acute
intermittent porphyria gene carriers were healthy.
For each acute intermittent porphyria gene carrier one non-porph-
yric control was chosen matching in age, gender and geographic
area. Nineteen of the 20 control persons selected took part in the
study, one 65 year old woman refusing participation. Ten of the
controls had hypertensive disease, two diabetes mellitus and one
Bechlerew's disease. Applying the same criteria as for the acute
intermittent porphyria gene carrier groups, the rest of the control
persons were healthy.
Mean age in the compound control group was 56 years, with a
range of 25—75 years. Male/female ratio was 12/7. The corre-
sponding figures for the acute intermittent porphyria group with a
history of porphyric symptoms was 54 years, 24—74 years and 6/4,
and for the asymptomatic acute intermittent porphyria group 58
years, 27—74 years and 6/4, respectively.
Determination of concentrations of trace elements in
blood cells and plasma
Concentrations of trace elements in erythrocytes and granulocytes
were determined by the technique of positron induced X-ray emis-
sion, using the Scanning Light Ion Microscope in Uppsala, Sweden
(Slim-Up). A complete description of the microscope and its per-
formance characteristics is found elsewhere (17), as are the pro-
cedures for blood sampling, preparation of the cells from venous
blood, the sample support technique and the sampling of individual
cells for investigation.
Trace elements in plasma were analysed in heparinized blood by
energy-dispersive X-ray fluorescence (18). Low-temperature ash-
ing was performed prior to analysis. Atomic absorption and graph-
ite furnace technique were used for the determinations of mercury,
aluminium and cadmium in plasma.
Determination of haem synthesizing enzymes
Venous blood was collected in heparinized tubes. For analysis of
erythrocyte porphobilinogen deaminase2) activity the blood was
centrifuged for ten minutes at 1500 g (rav = 11 cm) and the packed
red blood cells stored at —20 °C until assayed. Analysis of porpho-
bilinogen synthase2) activity was performed on whole blood stored
at —80 °C until assayed. For assay of erythrocyte uroporphyrino-
gen dccarboxylase2), blood was centrifuged for 15 minutes at 4 °C
and 2000 g (rav = 11 cm). The red cells were washed once with
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-* Fig. 1 A model of poiphyria as a condition of permanent system load of oxidative stress with
instances of periodic overload causing clinical symptoms.
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ice-cold saline, again centrifuged as described above and stored at
-80 °C until analysis. Lymphocyte pellets for Coproporphyrinogen
oxidase2), protoporphyrinogen oxidase2) and ferrochelatase2)
analysis were prepared immediately after blood collection. The
cells were isolated by density gradient centrifugation with Ficoll-
Paque (Pharmacia LKB, Uppsala, Sweden), and the pellets stored
at -80°C until assayed. Analysis of erythrocyte porphobilinogen
deaminase activity was made according to Magnussen et al. (19).
Ferrochelatase activity was determined as described by Nunn et
al. (20). The rest of the enzyme2) assays performed represented
modifications: porphobilinogen synthase (21, 22), uroporphyrino-
gen decarboxylase (23-25), Coproporphyrinogen oxidase (26, 27),
protoporphyrinogen oxidase (28-30). To avoid inter-assay varia-
tion each enzyme assay was performed in batch, including samples
from all individuals.
Determinat ion of serum variables
After overnight fast, venous blood was collected in tubes without
anticoagulant addition. Analyses of serum alanine aminotransfer-
ase, albumin, amylase, aspartate aminotransferase, bilirubin,
calcium, chloride, cholesterol, C-reactive protein, creatinine, cre-
atine kinase, glutamyl transpeptidase, lactate dehydrogenase, phos-
phate, potassium, sodium, uric acid and urea, were performed on
the automatic analyser Hitachi 737 and by use of reagents supplied
to the instrument (Boehringer Mannheim, Germany). Radioimrnu-
nological techniques were applied for the determinations of serum
cobalamin and folate (DPC Solid Phase No Boil Assay, LA, USA).
Serum ferritin was determined by enzyme-immunoassay (Enzy-
mun-Test® Ferritin, Boehringer Mannheim GmbH Diagnostica).
Free thyroxine and free triiodothyronine in serum were assayed by
a competitive immunoassay technique (Amerlite MAB FT4 Assay
and Amerlite FT3 Assay, Kodak Clinical Diagnostics LTD, Amers-
ham, UK). Serum human thyrotropin (hTSH) was analysed by im-
munoluminometric assay (Berlux® hTSH, Behringwerke AG, Mar-
burg, Germany).
Haematology
Blood haemoglobin and erythrocyte volume fraction were deter-
mined in venous EDTA-blood by use of the Sysmex NE-8000™
Automated Hematology Analyzer (TOA Medical Electronics CO,
LTD, Kobe, Japan). Erythrocyte sedimentation rate was measured
applying a technique based on sedimentation of the red blood cells
in the sampling tube (Becton Dickinson GmbH, Heidelberg, Ger-
many).
Analyses of glutathione peroxidase and Superoxide
dismutase activities
Whole blood glutathione peroxidase2) and Superoxide dismutase2)
activities were determined in heparinized blood, using the respec-
tive assays described elsewhere (31, 32).
Evaluat ion of food consumption patterns, smoking
habits and alcohol consumption
Food consumption patterns, alcohol consumption, and smoking
habits were evaluated in an interview situation by use of a stan-
dardized questionnaire. The variables investigated are presented
in table i.
Statistical methods
Linear discriminant analysis was performed on the whole material
to elucidate possible variables that could be used to group the cases
correctly (33). Equality of group covariance matrices was verified
by testing. Bivariate correlations were estimated by calculating the
product-moment correlation coefficients (34). .One way analysis of
variance was used to try whether some single variables in one
group differed significantly from the other groups, this was fol-
lowed by multiple range test by Duncan** method to assess exactly
which' groups differed (35). Comparisons between groups were
made by use of the Student's /-test, and relationships evaluated by
linear regression analysis.
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Results
When all variables investigated were included in the dis-
criminant analysis, it showed that leukocyte manganese
accounted for about 98 per cent of the variance between
the groups, and a history of a high consumption of mar-
malade and jam for about 2 per cent. About 97 per cent
of the grouped cases were correctly classified, only one
individual with asymptomatic porphyria being misclas-
sified into the symptomatic group. On exclusion of the
food consumption variables the only remaining signifi-
cant discriminant function was connected with leukocyte
manganese. About 87 per cent of cases were correctly
classified, four asymptomatic acute intermittent por-
phyria individuals being misclassified into the symptom-
atic group, and one acute intermittent porphyria gene
carrier with a history of porphyric symptoms incorrectly
placed in the asymptomatic group. All controls were
correctly classified. When only values for blood cell
trace elements were included in the linear discriminant
analysis, leukocyte manganese still accounted for the
only function of significance, more than 99 per cent of
the variance being attributed this variable. Half of the
asymptomatic cases of acute intermittent porphyria were
incorrectly placed in the symptomatic group, and three
of the ten acute intermittent porphyria individuals with
previous symptoms referred to the asymptomatic group.
All controls were correctly classified. Among the haem
synthetizing enzymes erythrocyte porphobilinogen de-
aminase alone contributed to the variance, allowing one
hundred per cent correct differentiation between gene
carriers and non-carriers, but not between cases with and
without a history of porphyric symptoms.
By analysis of variance, single variables differing be-
tween the groups were identified (fig. 2). Variables
which differ between the two acute intermittent por-
phyria groups and the control group are erythrocyte por-
phobilinogen deaminase and uroporphyrinogen decar-
boxylase activities, free erythrocyte porphyrin, leuko-
cyte manganese, iron, zinc and calcium, erythrocyte
calcium and serum calcium. Red cell porphobilinogen
synthase activity and serum cobalamin differ between
' the acute intermittent porphyria group with a history of
porphyric symptoms, on one hand, and the asymptom-
atic acute intermittent porphyria group and the controls
on the other. Also, consumption of marmalade and jam
is significantly higher in the group of previously symp-
tomatic acute intermittent porphyria as compared to the
other two groups. Serum aspartate aminotransferase is
higher in the group of acute intermittent porphyria in-
dividuals with a history of symptoms than in the control
group. Any differences between the groups with regard
to the rest of the variables are not observed.
In the group of asymptomatic acute intermittent por-
phyria gene carriers, as in contrast to the group with
previous porphyria symptoms and the controls, leuko-
cyte manganese and iron concentrations correlate
closely (fig. 3). Correlations between erythrocyte man-
ganese and serum folate, and between leukocyte fer-
rochelatase and serum cobalamin, are noted only in the
acute intermittent porphyria group with a history of
porphyric symptoms. In the group of controls, in con-
trast to the two acute intermittent porphyria groups, cor-
relations are noted between erythrocyte porphobilinogen
deaminase and uroporphyrinogen decarboxylase activi-
ties.
In the cases of the variables found to differ between the
two groups of porphyries and the non-porphyries (fig.
2) and/or exhibiting mutual correlations in one or two
of the groups (fig. 3), the dependence of age was studied
for the three different groups combined and separated,
respectively, and for the groups of males and females,
together and separated. In no case were the variables
found to be age or sex dependent (results not shown).
Within the group of acute intermittent porphyria with a
history of clinical symptoms, the same variables were
compared between individuals with different numbers of
porphyric attacks, differing with regard to recentness of
the last attack, and/or differing with respect of the sever-
ity of the clinical condition during attacks, respectively.
The observations are too few to allow statistical analy-
sis, but in most instances a more or less symmetrical
overlap of values was noted. Exceptions may be erythro-
cyte porphobilinogen synthase and uroporphyrinogen
decarboxylase activities, as seen in figure 4 (only results
from the analyses of haem synthetizing enzymes are
shown).
Discussion
The matching between the groups could be potentially
biased by the occurrence of current non-porphyric dis-
ease. However, in the case of diabetes mellitus, and
partly also hypertensive disease, the non-acute intermit-
tent porphyria control group were shown to match the
acute intermittent porphyria groups in this respect as
well. Also, in only one case, i. e. leukocyte ferrochela-
tase versus serum cobalamin in asymptomatic acute in-
termittent porphyria (fig. 3), the exclusion of values
from an individual with non-porphyric disease (diabetes
mellitus) resulted in a change in the statistical signifi-
cance from 0.52 to 0.70. In no other case did deletion of
such values affect significances between the compared
groups in any conclusive way.
The three groups investigated, i.e. acute intermittent
porphyria carriers without and with a history of porph-
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Fig. 2 Variables differing between presently asymptomatic acute intermittent porphyria individuals
without, and with a history of porphyric symptoms, and a matched control group respectively.
yric symptoms, and matched controls, were not shown
to differ with regard to the majority of the serum
analyses or haematological quantities acting as mark-
ers for disease. The exceptions were the levels of
serum aspartate aminotransferase and serum coba-
lamin, which were significantly higher in acute in-
termittent porphyria individuals with a history of porph-
yric illness than in the control group (fig. 2). This find-
ing, indicative of a subclinical hepatocyte membrane
damage (36), is compatible with a concept of an 5-
aminolaevulinic acid-triggered oxidative attack on the
liver tissue (37). . t
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Fig. 3 Correlations between variables within the groups of acute
intermittent porphyria individuals without, and with previous
porphyric symptoms, and within the group of control persons:
Acute intermittent porphyria without a history of porphyric illness:
Lkc-Mn/Lkc-Fe r = 0.994, p < 0.0001;
Ery-Mn/S-Folate r = 0.183, NS;
Lkc-Ferrochelatase/S-Cobalamin r = -0.515, NS;
Ery-Uroporphyrinogen decarboxylase/Ery-Porphobilinogen deami-
nase r = 0.078, NS.
Acute intermittent porphyria with a history of porphyric illness:
Lkc^Mn/LkcrFe r = -0.008, NS;
Ery-Mn/S-Folate r = 0.798, p < 0.01;
Lkc-Ferrochelatase/S-Cobalamin r = -0.798, p < 0.005;
Ery-Uroporphyrinogen decarboxylase/Ery-Porphobilinogen deami-
nase r = 0.432, NS.
Control group:
Lkc-Mn/Lkc-Fe r = 0.276, NS;
Ery-Mn/S-Folate r = -0.292, NS;
Lkc-Ferrochelatase/S-Cobalamin r = -0.079, NS;
Ery-Uroporphyrinogen decarboxylase/Ery-Porphobilinogen deami-
nase r = 0.763, p < 0.0001.
Lkc = leukocyte, Ery = erythrocyte, S = serum
Eur J Clin Chem Clin Biochem 1995; 33 (No 4)
188 Thuncll et al.: Markers for vulnerability in acute porphyria - A hypothesis .paper
I 6If ;
ll! iHI ο
1* 60ο ;> so
f.|x 30









ί 1 i* °·5



























































6 1 2? 0.1















[ " s so












a ί · ι
0.5
r . βο
. . . so
• · . · 40











































ο Λ « i § ο Less severely affected Severely affected
co -r- §̂  5; = ε ε Acute intermittent Acute intermittent
ο τ- co m ^ ' r - c v i ^ - porphyria porphyriaΛ τ - < 0 · ^ · ν r r i r r /
Number of attacks Time elapsed since Severity of
during the last year the last attack symptoms
Fig. 4 Values for erythrocyte and leukocyte activities of haem
synthetizing enzymes in previously symptomatic acute intermittent
porphyria individuals, grouped with regard to frequency, recentriess
and severity of the porphyric manifestations.
The high discriminative power of erythrocyte porphobil-
inogen deaminase activity as a marker for the acute in-
termittent porphyria gene carrier state (fig. 2) is an ex-
pected finding (38). In the present material, the diagnos-
tic power of the analysis is exceptionally high, no over-
lap being found between carriers and non-carriers of
acute intermittent porphyria. It is noted that gene carri-
ers for acute intermittent porphyria with and without
previous porphyric symptoms do not differ in erythro-
cyte porphobilinogen deaminase activity values. Differ-
ing activity of the erythroid enzyme product of the non-
affected porphobilinogen deaminase allele is thus not an
explanation for differences in porphyric morbidity in
acute intermittent porphyria.
In the group of previously symptomatic acute intermittent
porphyria individuals, but not in permanently asymptom-
atic acute intermittent porphyria or in controls, there is a
positive correlation between erythrocyte manganese and
serum folate, and a negative congelation between the ac-
Eur J Clin Chem Glin Biochem 1995; 33 (No 4)
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tivity of leukocyte ferrochelatase and the concentration of
cobalamin in serum (fig. 3). It has previously been re-
ported that folate deficiency may precipitate porphyric at-
tacks (39) and that administration of folic acid ameliorates
crises in acute porphyria (40), and the findings may be a
reflection of a role of the cobalamin-folate system in the
pathophysiology of acute porphyria.
In contrast to the observations in other studies (41) we
did not note any increases in erythrocyte levels of anti-
oxidant enzymes in acute intermittent porphyria. The
reason may be that our assays for Superoxide dismutase
and glutathione peroxidase, being performed on whole
blood, are not sensitive enough to register differences
between normal individuals and acute intermittent por-
phyria gene carriers in asymptomatic phase.
In the group of previously symptomatic acute intermittent
porphyria, erythrocyte porphobilinogen synthase activity
is higher than in the groups of permanently asymptomatic
acute intermittent porphyria and controls (fig. 2). The dif-
ference in porphobilinogen synthase activity was not
found to be accompanied by any change in the size of the
thiol activated fraction of the enzyme, and the activity is
not correlated to any other variable investigated. How-
ever, there is a tendency for a higher activity of the en-
zyme in red blood cells of individuals more recently af-
fected by clinical manifestations of acute intermittent por-
phyria (fig. 4), and the significantly higher porphobilino-
gen synthase activity in previously symptomatic
individuals is mainly due to their contributions. Evidently,
an attack of porphyric illness may be connected with a
transitory increase in the enzyme activity of the erythro-
cytes, recognizable during the month following the attack
and disappearing when a cohort of red cells present during
the crisis fades. In view of the proposed neurotoxicity of
accumulated 5-aminolaevulinic acid, it is conceivable that
the increased erythrocyte porphobilinogen synthase activ-
ity is a sign of a normoblast protective mechanism opera-
tive in acute intermittent porphyria aimed at eliminating
surplus 5-aminolaevulinic acid, by transformation to pre-
sumably less toxic porphobilinogen.
It has not previously been observed that erythrocyte uro-
porphyrinogen decarboxylase activity is decreased in
acute porphyria (fig. 2), and that there is a tendency
toward lower activity of this enzyme in patients with a
history of more recent, more frequent and/or more se-
vere porphyric conditions (fig. 4). As noted in figure 2,
the erythrocyte porphyrin content is higher in the groups
of acute intermittent porphyria gene carriers than in the
control group. Since it has been shown that uroporphyri-
nogen decarboxylase is sensitive to an inhibitor formed
on oxidation of its substrate, i. e. to uroporphyrin (42),
this finding may be due to a recent oxidative action of
unopposed free radicals on uroporphyrinogen (43), (fig.
1), resulting in inhibition of the decarboxylase and accu-
mulation of porphyrin not accessible for further bio-
transformation.
In non-porphyric individuals there is a correlation be-
tween erythrocyte porphobilinogen deaminase and uro-
porphyrinogen decarboxylase activities not found in
porphyries (fig. 3). This may be a reflection of an inter-
regulation of these two enzymes working normally, but
failing at the low porphobilinogen deaminase activities
in acute intermittent porphyria and during porphyric
conditions of uroporphyrinogen decarboxylase inhibi-
tion. The activities of these cytoplasmatic enzymes in
red blood cells should normally be determined mainly
by the activities of the two pairs of alleles, one for each
enzyme, that code for the active proteins, the expres-
sions of which, conceivably, may be coupled and inter-
regulated. At a given time the activities of porphobilino-
gen deaminase and uroporphyrinogen decarboxylase
thus would correlate, and largely be determined by the
actual size of the circulating cohort of erythrocytes with
still conserved enzyme contents, i. e. younger cell ele-
ments. If one allele in one of the two pairs is silent, as
is the case with the porphobilinogen deaminase produc-
ing gene in acute intermittent porphyria, a synchronised
interregulation of the two enzymes would fail and
changes in enzyme activities would not be proportional.
In the case of partial inhibition of the active gene pro-
duct of the other pair, i. e. of uroporphyrinogen decar-
boxylase, a gene regulated connection between the two
enzyme activities would be further disturbed, resulting
in correlation patterns like those observed in the pre-
sent study.
Experimental, and in several cases also clinical evidence
point to the fact that certain metals and transition ele-
ments as well as herbicides used in agriculture and food
handling may have the capacity to precipitate illness in
the inducible porphyrias (fig. 1). Consequently, individ-
uals carrying a gene for acute hepatic porphyria are ad-
vised to avoid exposition to such agents. In the present
material we have not been able to document any differ-
ences in plasma concentration of lead, mercury, cad-
mium, iron, copper, aluminium, zinc, magnesium, man-
ganese or selenium which can serve as an explanation
for porphyric vulnerability. Nor are any differences in
alcohol consumption or smoking habits noted. The ob-
servation that individuals with previous acute intermit-
tent porphyria symptoms consume significantly more
marmalade and jam probably reflects an adaptive behav-
iour aimed to benefit from the prophylactic effect of the
sugar component of these food-stuffs. In other respects
the food consumption patterns do not differentiate be-
tween the groups studied, and can thus not explain the
differences in porphyric vulnerability.
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In contrast, leukocyte levels of manganese, iron, calcium
and zinc are found to be considerably higher in individ-
uals carrying the acute intermittent porphyria gene than
in non-carriers (fig. 2). They also show higher levels of
erythrocyte calcium and lower concentrations of serum
calcium. The values for these variables do not differ be-
tween acute intermittent porphyria individuals with and
without a history of porphyric symptoms. Increases of
leukocyte manganese, calcium and iron concentrations
have been observed in inflammatory disease (44). In the
present material only one person within the acute in-
termittent porphyria group was affected by such a condi-
tion. The rest exhibited normal values for inflammatory
markers in blood. Since the study was performed in a
non-symptomatic phase of acute intermittent porphyria
it seems improbable that the changes should represent
reactive blood cell responses to active porphyric illness.
Manganese proved to be the paramount discriminative
component among the 78 variables investigated. This el-
ement is a potent modulator of a multitude of signal
transduction pathways in the body (45). If the increased
leukocyte contents of this element is a reflection of a
generalized cellular condition, many of its documented
biological effects are of potential interest in the pursuit
of an explanation for the pathogenesis of porphyric ill-
ness. It seems, however, less probable that an element
such as manganese should exist in cells in free form in
concentrations as high as those noted in porphyria, with-
out resulting in cell damage. More likely it is bound to
proteins with specific functions, and the activity of any
of the manganese associated enzymes glutamine syn-
thetase, pyruvate carboxylase and mitochondrial super-
oxide dismutase (46-48) may be of functional rele-
vance in the porphyric condition.
Eighty per cent of the manganese in the brain is associ-
ated with glutamine synthetase (49). This enzyme catal-
yses the formation of glutamine from the fast acting so-
matosensory transmitter glutamate (50). It is interesting
to note that the substrate for glutamine synthetase is the
immediate precursor of the neuroactive 5-aminolaevuli-
nic acid analogue γ-amino butyric acid, and that an
increased activity of the enzyme thus will also affect the
availability of this neurotransmitter.
The product of the pyruvate carboxylase reaction is oxa-
loacetate. This compound is both a stoichiometric inter-
mediate in gluconeogenesis and a catalytic intermediate
in the citric acid cycle (51). The fate of oxaloacetate
depends on the energy state of the cell. In an ATP defi-
cient situation a large output of oxaloacetate will give
rise to a potentially porphyrinogenic situation by being
channelled into the citric acid cycle, thus adding to the
pool of the porphyrinogen precursor succinyl-CoA. An
overexpression of the enzyme, or induction secondary
to a deficient energy production, will thus add to the
strain on the weak porphobilinogen deaminase step in
acute porphyria. This would explain the phenomenon
that porphyric individuals in several cases develop neu-
ropsychiatric manifestations on porphobilinogen deami-
nase enzyme levels which in non-cfirriers of a porphyric
gene are not associated with porphyric symptomatology.
It also gives a further rationale for the therapeutic use
of glucose in acute porphyric crises.
The best fit into the pathogenetic model tested is pro-
vided by the manganese based mitochondrial Superoxide
dismutase. This metalloenzyme is induced under condi-
tions associated with production of Superoxide anion
(52). In view of the findings in inflammatory disease
it is conceivable that the high granulocyte manganese
contents in porphyria is a reflection of such an induction
secondary to oxidative stress (fig. 1). The increased cel-
lular contents of iron in acute intermittent porphyria
gene carriers observed in the present study (tab. 2), is of
considerable interest in this context, since the ferrous
form of this element participates in the generation of
oxygen radicals from 5-aminolaevulinic acid, and also
plays a central role in the superoxide^-driven Fentoh's
chemistry (53) which generates toxic hydroxyl radicals
(fig. 1). Further, it is noteworthy that in the permanently
asymptomatic acute intermittent porphyria individuals
seemingly resistent to porphyric illness, increased levels
of iron are matched by increments in manganese, i. e.
according to the model exploited, by an induction of
mitochondrial Superoxide dismutase. This correlation is
not present in acute intermittent porphyria individuals
prone to symptom development, which may be interpre-
ted as the abscence of an important antiporphyrinogenic,
and protective, factor.
The fact that the increase in cellular manganese is also
observed in currently asymptomatic acute intermittent
porphyria suggests a permanent production of reactive
oxygen species in the porphyria gene carrier state. An
unlimited source for reactive oxygen in acute hepatic
porphyria is 5-aminolaevulinic acid (11, 12, 41, 54), and
it is likely that 5-aminolaevulinic acid derived oxygen
radicals are produced locally within a nervous tissue
sharing the genetic porphobilinogen deaminase defect in
acute intermittent porphyria. Aminolaevulinate has been
shown to give rise to mitochondrial damage (37), evi-
dently due to lipid peroxidation (55). Since nervous tis-
sue is known to be exceptionally sensitive to free radical
injury (56), a steady generation of 5-aminolaevulinate
within the nerve cell would build up a potentially injuri-
ous hyperoxidative state. It has also been observed that
reactive oxygen metabolites derived from blood can pro-
duce damages to extravascular tissue (57), and such in-
crements in free radical activity syould add to the oxida-
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tive stress within the nervous system. A possible source
for reactive oxygen species is tumour necrosis factor or
interleukin-1 acting on susceptible cells, processes
which have been observed to give rise to induction of
mitochondrial Superoxide dismutase (58, 59). At the pre-
sent, however, no model is available for an interconnec-
tion of cytokines and granulocyte manganese Superoxide
dismutase induction in non-symptomatic acute intermit-
tent porphyria gene carrier states.
In acute porphyria regarded as a state of augmented gen-
eration of partially reduced oxygen, local variations in
the balance between pro- and antioxidants can explain
the varying susceptibility to porphyric neuropathy and
also determine the actual locations of the lesions within
the nervous system. A continuous input of energy is
needed for the channelling of reactive oxygen species
into less harmful products. If energy production is im-
paired, as it may permanently be in a haem deficit situa-
tion resulting from a porphyric block in the pathway,
this protective mechanism is weakened, especially under
circumstances of caloric restriction. This may be one
reason for the precipitation of porphyric attacks by fast-
ing. Assuming the cell has sufficient components at its
disposal in the radical defence system with the capacity
to prevent the formation of the hydroxyl radical, or neut-
ralize its effect, the induction of Superoxide dismutase
gives rise to a strong protective potential, directing hy-
droxyl radicals away from the cell damaging hydroper-
oxyl radical pathway (60), (fig. 1). On the other hand, if
the activity of glutathione peroxidase is low, e. g. sec-
ondary to deficits in selenium or cysteine, or if the pro-
duction of catalase is impaired, which may be the case
in conditions where haem synthesis is disturbed, toxic
hydroxyl radicals are produced in proportion to the de-
gree of Superoxide dismutase induction. These are neu-
tralized by fatty acids, but if the regeneration of these
molecular species is inhibited for lack of vitamin E, ß-
carotene and/or for the endogenously produced carnit-
ine, taurine and ubiquinone, unopposed reactive hy-
droxyl radicals will eventually be generated and give
rise to damage to cellular nucleic acid, protein and lipid
constituents (53, 61—64). Differences in the supply of
compounds with antioxidant action may, by these mech-
anisms, account for differences in porphyric morbidity.
A mechanism amplifying the porphyrinogenic action of
reactive oxygen species is found in their effects on the
throughput of the glyoxalase cycle. If the conversion
of dioxovaleric acid is inhibited by a deficit in reduced
glutathione, e. g, arising from a consumption of this sub-
stance secondary to handling of an increased load of
hydrogen peroxide, or because of a haem-deficit derived
impairment of oxidative metabolism (fig. 1), more of
this compound will be directed into the haem synthetic
pathway, and further equivalents of reactive oxygen,
originating from the increased synthesis of 5-aminolae-
vulinic acid will be produced. The same is the case if
the enzymatic conversion of dioxovaleric acid is inter-
fered with by inhibition of glyoxalase activity by certain
drugs and hormones (65).
In the model of acute porphyria as a hyperoxidative con-
dition, the profound therapeutic effect of administered
haematin (66) is explained by its inhibitory action on
the conversion of dioxovaleric acid to 5-aminolaevulinic
acid (67), as well as by the inhibition of aminolaevuli-
nate synthase induction. Also, haematin is one of the
most effective iron chelators for catalysis of the decom-
position of hydrogen peroxide to water (53), an activity
compensating for failing glutathione peroxidase and cat-
alase activities. The porphyrinogenic properties of e. g.
barbiturates and oestrogen, as well as the negative ef-
fects in porphyria of low caloric intake, smoking and
infection, may be secondary to the radical enhancing
effects of these external agents. Similarly, the negative
effect of carbohydrate restriction and the existence of
the therapeutically exploited "glucose effect" in acute
porphyria (68) may be explained on basis of the protec-
tive action of glucose in oxidative stress (69). The noto-
rious porphyrinogenic action of ethanol can be due to
impairment of the glutathione peroxidase pathway for
disposing of hydrogen peroxide. The reason would be
found in a depletion of reduced glutathione secondary
to NADPH consumption (70) and subsequent reduction
of the cellular thiol pool. The latter mechanism also ac-
counts for the attack triggering effect of environmental
stress. A rationale for the, anecdotic, use of permanent
bicarbonate medication in acute intermittent porphyria,
is obtained by the dependency of acid pH of the pro-
cesses liberating prooxidant catalytic ferrous iron from
protein chelators. Also, the generation of highly toxic
peroxyl radicals from Superoxide anions is favoured by
an acidic pH (53).
Another mechanism behind a rise in intracellular manga-
nese, and resulting in augmented production of free radi-
cals, would be a primary overexpression of the gene for
mitochondrial Superoxide dismutase (71). In the dismu-
tation reaction the enzyme exhibits a bell-shaped protec-
tive effect against free radicals, at higher as well as
lower concentrations giving way for increased lipid per-
oxidation (72, 73). The Superoxide dismutase also cata-
lyzes the formation of hydroxyl radical from hydrogen
peroxide (74), and the generation of peroxynitrite from
nitric oxide and Superoxide which decomposes to the
highly reactive hydroxyl free radical (75). These para-
doxical effects of Superoxide dismutase may be of signi-
ficance in porphyric neuropathy, as a high expression of
mutant Superoxide dismutase in mice has been observed
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to cause damages to the ventral «horn neurons of the spi-
nal cord, i. e. the part of the nervous system taking the
brunt of the damage in human acute porphyria (76, 77).
Since nitric oxide modulates the effects of free radical
species (78), the selective vulnerability of neurological
tissues accounting for the porphyric neuropsychiatric
syndrome, may be due to variations in the expression
and inducibility of the nitric oxide synthases responsible
for the local generation of the gas.
The well known association between the acute porphyria
gene carrier state and liver cancer (79, 80) is explained
by a theory of permanent oxidative stress. Cancer devel-
opment requires one half to two thirds of the life span of
the organism, and a long standing production of partially
reduced oxygen in porphyria would, if unopposed, cause
DNA damages (12) and initiate neoplastic transforma-
tion (81, 82). Constrictive response in the glomerular
microcirculation, provoked by reactive oxygen species,
can be the reason for the kidney engagement (57, 83).
Cell membrane permeability changes induced by free
radicals and accompanied by entry of calcium may ac-
count for the finding of increased erythrocyte calcium
in the acute intermittent porphyria gene carrier state (fig.
2). Ionized calcium derived from extracellular sources
can, under certain conditions, promote a calmodulin de-
pendent Superoxide radical production (84), and in ner-
vous tissue a loss of calcium homeostasis resulting in
elevated intracellular calcium activity causes structural
damage to neurons and results in cell death (85).
The observations in the present study are compatible
with a theory of clinical acute intermittent porphyria as
a radical powered process, secondary to a steady pro-
duction of reactive oxygen species within the nervous
system, and aggravated by increments in the oxidative
stress level caused by temporary increases in 5-amino-
laevulinic acid production and/or contributions of radi-
cals from other sources. The localisation to nervous tis-
sue may depend on the local balance at critical anatomi-
cal sites between enhancers and protectors for oxidative
stress. The model comprises several balance points be-
tween pro- and antioxidant forces, triggering points for
selfrecruiting radical generating circuits, and critical
factors on which the antioxidant system is dependent of
a constant supply, or which are prey to expediture by
consumption. Such a labile system, fluctuating around a
basal level of 5-aminolaevulinic acid-driven oxidative
challenge varying in magnitude between different in-
dividuals, and within one individual at different times,
would account for the unpredictable outcome of the por-
phyria gene carrier state, and for the sinister long term
effects of the porphyric condition on hepatic and renal
tissues. The findings bring up the question whether
porphyric vulnerability may be due to failure of the pro-
tective interplay between mitochondrial Superoxide dis-
mutase and intracellular ferrous iron. Interpretations fo-
cused on manganese associated enzymes other than
mitochondrial Superoxide dismutase, however, stand
open and further studies are needed to elucidate the
pathophysiological implications of the granulocyte trace
element increments and enzymatic aberrations observed
in the major Swedish mutation of acute intermittent
phyria.
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